Danimer Scientific (DNMR) 10-Q 9 Aug 22 2022 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 09, 2022
Document Information [Line Items]
Entity Registrant Name	DANIMER SCIENTIFIC, INC.
Entity Central Index Key	0001779020
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39280
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	84-1924518
Entity Address, Address Line One	140 Industrial Boulevard
Entity Address, City or Town	Bainbridge
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	39817
City Area Code	229
Local Phone Number	243-7075
Title of 12(b) Security	Class A Common stock, $0.0001 par value per share
Trading Symbol	DNMR
Security Exchange Name	NYSE
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		101,170,634

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 140,388	$ 286,487
Accounts receivable, net	18,224	17,149
Other receivables, net	1,408	3,836
Inventories, net	32,729	24,573
Prepaid expenses and other current assets	5,394	4,737
Contract assets, net	3,900	3,576
Total current assets	202,043	340,358
Property, plant and equipment, net	408,885	316,181
Intangible assets, net	82,495	84,659
Goodwill	62,663	62,649
Right-of-use assets	19,133	19,240
Leverage loans receivable	13,408	13,408
Restricted cash	449	481
Loan fees	1,413	1,397
Other assets	228	224
Total assets	790,717	838,597
Current liabilities
Accounts payable	11,748	20,790
Accrued liabilities	10,994	18,777
Unearned revenue and contract liabilities	2,290	214
Current portion of lease liability	3,337	3,337
Current portion of long-term debt, net	2,242	357
Total current liabilities	30,611	43,475
Private warrants liability	2,571	9,578
Long-term lease liability, net	22,412	22,693
Long-term debt, net	262,032	260,934
Deferred income taxes	483	1,014
Other long-term liabilities	753	638
Total liabilities	318,862	338,332
Commitments and contingencies (Note 15)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized: 101,114,861 and 100,687,820 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	10	10
Additional paid-in capital	647,566	619,145
Accumulated deficit	(175,721)	(118,890)
Total stockholders’ equity	471,855	500,265
Total liabilities and stockholders’ equity	$ 790,717	$ 838,597

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	101,114,861	100,687,820
Common Stock, Shares, Outstanding	101,114,861	100,687,820

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Total revenue	$ 12,703	$ 14,471	$ 27,446	$ 27,652
Costs and expenses:
Cost of revenue	14,934	12,460	30,999	24,185
Selling, general and administrative	20,975	19,079	43,211	29,199
Research and development	8,913	3,975	16,044	6,594
Loss on sale of assets	1	33	1	33
Total costs and expenses	44,823	35,547	90,255	60,011
Loss from operations	(32,120)	(21,076)	(62,809)	(32,359)
Nonoperating income (expense):
Gain (loss) on remeasurement of private warrants	2,012	58,740	7,007	(21,957)
Interest expense, net	(652)	(203)	(1,644)	(352)
Gain on forgiveness of debt		1,776		1,776
Loss on loan extinguishment				(2,604)
Other, net	75	11	84	10
Total nonoperating income (expense):	1,435	60,324	5,447	(23,127)
(Loss) income before income taxes	(30,685)	39,248	(57,362)	(55,486)
Income taxes	240		531
Net (loss) income	$ (30,445)	$ 39,248	$ (56,831)	$ (55,486)
Net loss per share:
Basic net (loss) income per share	$ (0.30)	$ 0.44	$ (0.56)	$ (0.64)
Diluted net (loss) income per share	$ (0.30)	$ 0.39	$ (0.56)	$ (0.64)
Weighted average number of shares used to compute
Basic net (loss) income per share	101,047,650	88,806,086	100,888,185	86,760,615
Effect of dilutive instruments		12,718,858
Diluted net (loss) income per share	101,047,650	101,524,944	100,888,185	86,760,615
Products
Revenue:
Total revenue	$ 11,575	$ 11,294	$ 24,791	$ 22,318
Services
Revenue:
Total revenue	$ 1,128	$ 3,177	$ 2,655	$ 5,334

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Total stockholders’ equity		$ 8	$ 414,819	$ (58,783)
Balance, beginning of period at Dec. 31, 2020		8	414,819	(58,783)
Fair value of private warrants converted to public warrants			45,515
Stock-based compensation expense			20,696
Stock issued under stock compensation plan			2,466
Issuance of common stock, net of issuance costs		1	(890)
Exercise of warrants, net of issuance costs			138,202
Net (loss) income	$ (55,486)			(55,486)
Balance, end of period at Jun. 30, 2021	506,548	9	620,808	(114,269)
Total stockholders’ equity		8	435,782	(153,517)
Balance, beginning of period at Mar. 31, 2021		8	435,782	(153,517)
Fair value of private warrants converted to public warrants			31,593
Costs related to warrants			0
Stock-based compensation expense			14,031
Stock issued under stock compensation plan			1,275
Issuance of common stock, net of issuance costs		1	(75)
Exercise of warrants, net of issuance costs			138,202
Net (loss) income	39,248			39,248
Balance, end of period at Jun. 30, 2021	506,548	9	620,808	(114,269)
Total stockholders’ equity	506,548	9	620,808	(114,269)
Total stockholders’ equity	500,265	10	619,145	(118,890)
Balance, beginning of period at Dec. 31, 2021	500,265	10	619,145	(118,890)
Fair value of private warrants converted to public warrants			0
Costs related to warrants			(55)
Stock-based compensation expense			27,983
Stock issued under stock compensation plan			493
Issuance of common stock, net of issuance costs		0	0
Exercise of warrants, net of issuance costs			0
Net (loss) income	(56,831)			(56,831)
Balance, end of period at Jun. 30, 2022	471,855	10	647,566	(175,721)
Total stockholders’ equity		10	633,213	(145,276)
Balance, beginning of period at Mar. 31, 2022		10	633,213	(145,276)
Fair value of private warrants converted to public warrants			0
Costs related to warrants			0
Stock-based compensation expense			14,233
Stock issued under stock compensation plan			120
Issuance of common stock, net of issuance costs		0	0
Exercise of warrants, net of issuance costs			0
Net (loss) income	(30,445)			(30,445)
Balance, end of period at Jun. 30, 2022	471,855	10	647,566	(175,721)
Total stockholders’ equity	$ 471,855	$ 10	$ 647,566	$ (175,721)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (56,831)	$ (55,486)
Adjustments to reconcile net loss to net cash used in operating activities
Gain on remeasurement of private warrants	(7,007)	21,957
Share-based compensation	27,983	20,696
Depreciation and amortization	8,588	4,311
Inventory reserves	597
Deferred income taxes	(531)
Loss on write-off of deferred loan costs		1,900
Amortization of debt issuance costs and debt discounts	1,152	207
Gain on forgiveness of debt		(1,776)
Amortization of right-of-use assets and lease liability	(173)	(806)
Contract asset reserve	1,216
Other	872	66
Changes in operating assets and liabilities, net of effects of aquisitions:
Accounts receivable, net	(2,166)	(3,229)
Other receivables	2,692	(235)
Inventories	(10,838)	(4,011)
Prepaid expenses and other current assets	1,434	(1,520)
Contract assets	(1,540)	(1,552)
Other assets	(5)	40
Accounts payable	(2,693)	1,967
Accrued and other long-term liabilities	(2,220)	(3,537)
Unearned revenue and contract liabilities	2,077	(1,633)
Net cash used in operating activities	(37,393)	(22,641)
Cash flows from investing activities
Purchases of property, plant and equipment	(108,850)	(51,906)
Acquisition of Novomer, net of cash acquired	(14)
Proceeds from sales of property, plant and equipment	55	340
Net cash used in investing activities	(108,809)	(51,566)
Cash flows from financing activities
Proceeds from exercise of warrants, net of issuance costs		138,202
Proceeds from long-term debt		169
Cash paid for debt issuance costs	(279)	(1,684)
Proceeds from exercise of stock options	197	2,375
Proceeds from employee stock purchase plan	296	92
Principal payments on long-term debt	(88)	(27,075)
Cost related to warrants	(55)
Proceeds from issuance of common stock, net of issuance costs		(890)
Net cash provided by financing activities	71	111,189
Net (decrease) increase in cash and cash equivalents and restricted cash	(146,131)	36,982
Cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash-beginning of period	286,968	379,897
Cash and cash equivalents and restricted cash-end of period	140,837	416,879
Supplemental Cash Flow Information [Abstract]
Cash paid for interest, net of interest capitalized	481	242
Cash paid for operating leases	1,771	1,589
Inventory consumed in constructing property, plant and equipment	2,084
Changes in accounts payable and accrued liabilities related to purchase of PP&E	$ (11,797)	$ 5,983

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Note 1. Basis of Presentation Description of Business Danimer Scientific, Inc., together with its subsidiaries (“Company”, “Danimer”, “we”, “us”, or “our”), is a performance polymer company specializing in bioplastic replacements for traditional petroleum-based plastics. Our common stock is listed on the New York Stock Exchange under the symbol “DNMR”. The Company (formerly Live Oak Acquisition Corp. (“Live Oak”)), was originally incorporated in the State of Delaware on May 24, 2019 as a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses. Live Oak completed its initial public offering in May 2020. On December 29, 2020, Live Oak consummated a business combination (“Business Combination”) pursuant to an Agreement and Plan of Merger, dated as of October 3, 2020 (as amended by Amendment No. 1, dated as of October 8, 2020, and Amendment No. 2, dated as of December 11, 2020 (collectively “Merger Agreement”), by and among Live Oak, Green Merger Corp. (“Merger Sub.”), and Meredian Holdings Group, Inc. (“Legacy Danimer”). Immediately upon consummation of the Business Combination, Merger Sub. merged with and into Legacy Danimer, with Legacy Danimer surviving the merger as a wholly owned subsidiary of Live Oak. In connection with the Business Combination, Live Oak changed its name to Danimer Scientific, Inc. On August 11, 2021, we closed the acquisition of Novomer, Inc. (integrated into our business as “Danimer Catalytic Technologies”). Our consolidated results include those of Danimer Catalytic Technologies from the acquisition date forward. Refer to Note 2 for further discussion of the acquisition. Financial Statements The accompanying condensed consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and consolidate all assets and liabilities of the Company and its wholly owned subsidiaries. GAAP requires us to make certain estimates and assumptions in recording assets, liabilities, sales and expenses as well as in the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. All intercompany transactions and balances have been eliminated. Certain reclassifications have been made to previously reported amounts to conform to the current presentation. In preparing these condensed consolidated financial statements, we have considered and, where appropriate, included the effects of the COVID-19 pandemic on our operations. The pandemic continues to provide significant challenges to the U.S. and global economies. Since we do no t have any items of other comprehensive income or loss, there is no difference between net (loss) income and comprehensive (loss) income for the three and six month periods ended June 30, 2022 or 2021, so a separate condensed consolidated statement of comprehensive (loss) income that would otherwise be required is not presented. Recently Issued Accounting Pronouncements There have been no new accounting pronouncements not yet effective that we believe will have a significant effect, or potential significant effect, on our condensed consolidated financial statements.

Business Combination

Business Combination	6 Months Ended
	Jun. 30, 2022
Business Combinations [Abstract]
Business Combination	Note 2. Business Combination Danimer Catalytic Technologies On August 11, 2021, we acquired all of the outstanding shares of Novomer, Inc., a privately held company, in exchange for $ 153.9 million in cash, gross of cash acquired, subject to certain customary adjustments as set forth in the merger agreement. We also entered into employment or consulting agreements with, and granted stock options to, certain key employees and consultants of Novomer Inc. We have also recorded contingent purchase price payable that will be payable to the sellers upon our collection of an income tax refund receivable. We have integrated Novomer, Inc. into our business as Danimer Catalytic Technologies. Danimer Catalytic Technologies uses its proprietary thermal catalytic conversion process to produce a unique type of PHA, referred to under its brand name as Rinnovo, that can be incorporated into some of our products as a complement to our existing PHA polymer at reduced cost. The table below sets forth the preliminary fair values of assets acquired and liabilities assumed including the adjustments recorded in the six months ended June 30, 2022: December 31, June 30, (in thousands) 2021 Adjustments 2022 Cash and restricted cash $ 2,741 $ - $ 2,741 Property, plant and equipment 18,622 - 18,622 Other assets acquired 2,302 - 2,302 Right-of-use asset 2,715 - 2,715 Acquired technology 84,400 - 84,400 Goodwill 62,649 14 62,663 Deferred tax liability ( 14,246 ) - ( 14,246 ) Lease liability ( 2,759 ) - ( 2,759 ) Liabilities assumed ( 2,004 ) ( 14 ) ( 2,018 ) Contingent purchase price payable ( 500 ) - ( 500 ) Total preliminary purchase price $ 153,920 $ - $ 153,920 We have recognized the assets acquired and liabilities assumed at their estimated acquisition date fair values, with the excess of the purchase price over the estimated fair values of the identifiable net assets acquired recorded as goodwill. The accounting for the business combination is based on currently available information and is considered preliminary. The final accounting for the business combination may differ materially from that presented above as future events may provide additional information about the realizability of other assets or the existence of other liabilities at the acquisition date. In addition, income tax returns for 2021 have yet to be filed, and we are validating certain state income tax allocations, which could result in changes to acquisition-date deferred tax liability. The preliminary estimated goodwill is attributable to the strategic opportunities and synergies that we expect to arise from the acquisition and the value of its existing workforce. The goodwill is not deductible for federal income tax purposes. The following table compares pro forma revenue and loss from operations for the combined entity for the three and six months ended June 30, 2021 as if the acquisition had taken place on January 1, 2021 to actual results for the three and six months ended June 30, 2022. These pro forma results do not necessarily reflect what the combined entity's results would have been had the acquisition taken place at that time, and this pro forma financial information may not be useful in predicting our future financial results. The actual results might have differed significantly from the pro forma amounts reflected herein due to a variety of factors. The following includes pro forma adjustments to reflect amortization of acquired technology intangible assets. We do not disclose pro forma impact related to income taxes or earnings-per-share as we do not believe those are useful to the reader in our situation. Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Revenue $ 12,703 $ 14,492 $ 27,446 $ 27,687 Loss from operations ( 32,120 ) ( 23,921 ) ( 62,809 ) ( 40,193 ) During the three and six months ended June 30, 2022, Danimer Catalytic Technologies incurred $ 2.9 and $ 5.8 million in expenses, respectively, including amortization expense.

Fair Value Considerations

Fair Value Considerations	6 Months Ended
	Jun. 30, 2022
Fair Value Considerations [Abstract]
Fair Value Considerations	Note 3. Fair Value Considerations Fair value is defined as the price we would receive to sell an asset, or pay to transfer a liability, in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. GAAP provides a three-tier hierarchy for measuring fair value based on the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of the fair value hierarchy are as follows: Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities; Level 2 - Observable inputs other than quoted prices in active markets, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; and Level 3 - Unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. Level 1 The carrying amounts of our cash and cash equivalents and restricted cash were measured using quoted market prices in active markets and represent Level 1 investments. Our other financial instruments such as accounts receivable, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair value of our Notes (see Note 11), based on trades made around June 30, 2022, was approximately $ 186.1 million. We value our restricted stock that does not include market or performance factors at the closing price of a share of our common stock on the grant date. We value our restricted stock with performance factors at the closing price of a share of our common stock on each period end date, or $ 4.56 at June 30, 2022, since such grants include a cash settlement feature. Level 2 We value our restricted stock that contain a market-based vesting provision using a Monte Carlo simulation, which takes into account a large number of potential stock price scenarios over time and incorporates varied assumptions about volatility and exercise behavior for those various scenarios. These assumptions are based on market data but cannot be directly observed. A fair value is determined for each potential outcome. There were no restricted stock units that contained a market-based vesting condition issued during the three and six months ended June 30, 2022. Level 3 We use the Black-Scholes option pricing model to value stock options, including ESPP awards, and our outstanding warrants to purchase shares of our common stock at an exercise price of $ 11.50 per share, subject to adjustments, that had been privately placed prior to the Business Combination (“Private Warrants”). The Private Warrants and stock options with a cash-settlement feature are re-valued each period end, and all other stock options are valued on the date of grant only. Other than this mark to market factor, we recognize this expense on a straight-line basis over the respective vesting periods. Since our stock price history as a publicly traded company is shorter in duration than the expected lives of our options (other than ESPP awards), we use a peer group to assess volatility. We have not paid and do not currently anticipate paying a cash dividend on our common stock, so we have set the expected annual dividend yield to zero for all calculations. We used risk-free rates equal to the U.S. Treasury yield curves in effect as of the valuation dates for durations equal to the expected lives of each option. We use the simplified method under Staff Accounting Bulletin Topic 14, defined as the mid-point between the vesting period and the contractual term for each grant, to determine the expected lives of stock options and we use the remaining contractual life of the warrants as their expected life. The following table sets forth the fair values we calculated and the ranges of values used in our Black Scholes calculations for stock options, other than ESPP awards. June 30, Three Months Ended June 30, 2022 2022 2021 Share prices of our common stock $ 4.56 $ 4.04 - $ 4.56 $ 15.89 - $ 38.33 Expected volatilities 47.05 % 45.72 % - 47.39 % 41.50 % - 41.50 % Risk-free rates of return 2.97 % 2.81 % - 2.98 % 1.05 % - 1.05 % Expected option terms (years) 5.28 5.06 - 6.00 6.00 - 6.00 Calculated option values $ 1.05 $ 0.33 - $ 2.32 $ 18.52 - $ 18.52 The table below sets forth the inputs we used in our Black Scholes models for Private Warrants valuations and the fair values determined. June 30, December 31, 2021 Share price of our common stock $ 4.56 $ 8.52 Expected volatility 50.9 % 47.6 % Risk-free rate of return 2.95 % 1.11 % Expected warrant term (years) 3.50 3.99 Fair value determined per warrant $ 0.66 $ 2.45

Inventories, net

Inventories, net	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventories	Note 4. Inventories, net Inventories, net consisted of the following: June 30, December 31, (in thousands) 2022 2021 Raw materials $ 18,535 $ 11,555 Work in process 981 928 Finished goods and related items 13,213 12,090 Total inventories, net $ 32,729 $ 24,573 At June 30, 2022 and December 31, 2021, finished goods and related items included $ 5.9 million and $ 5.6 million of finished neat PHA. Inventory at June 30, 2022 is stated net of reserves of $0.6 million related to interim assessments to reduce the carrying value of inventory to the lower of cost or net realizable value.

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, net	Note 5. Property, Plant and Equipment, net Property, plant and equipment, net, consisted of the following: June 30, December 31, (in thousands) Estimated Useful Life (Years) 2022 2021 Land and improvements 20 $ 92 $ 92 Leasehold improvements Shorter of useful life or lease term 28,036 27,845 Buildings 15 - 40 2,156 2,156 Machinery and equipment 5 - 20 100,977 97,923 Motor vehicles 7 - 10 921 912 Furniture and fixtures 7 - 10 443 420 Office equipment 3 - 10 3,509 3,368 Construction in progress N/A 308,148 212,647 444,282 345,363 Accumulated depreciation and amortization ( 35,397 ) ( 29,182 ) Property, plant and equipment, net $ 408,885 $ 316,181 We reported depreciation and amortization expense (which included amortization of intangible assets) as follows: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Cost of revenue $ 2,289 $ 1,951 $ 4,517 $ 3,790 Selling, general and administrative 163 177 323 273 Research and development 1,876 83 3,748 248 Total depreciation and amortization expense $ 4,328 $ 2,211 $ 8,588 $ 4,311 Construction in progress consists primarily of the early stages of construction of our Greenfield facility in Bainbridge, Georgia and the build-out of our facility in Winchester, Kentucky, as noted in the table below. June 30, December 31, Georgia $ 155,329 $ 83,660 Kentucky 150,016 128,289 New York 2,803 698 $ 308,148 $ 212,647 We anticipate placing the Phase II expansion of our facility in Winchester, Kentucky in service during the quarter ending September 30, 2022. We do not have an expected in-service date for our Greenfield facility in Bainbridge, Georgia at this time, since that project is still in an early stage of completion. Property, plant and equipment includes gross capitalized interest o f $ 9.3 million and $ 5.7 million as of June 30, 2022 and December 31, 2021, respectively. For the three months ended June 30, 2022 and 2021, interest costs of $ 2.0 million and $ 0.05 million, respecti vely, were capitalized to property, plant and equipment. For the six months ended June 30, 2022 and 2021, interest costs of $ 3.6 million and $ 0.3 million, respecti vely, were capitalized to property, plant and equipment.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Note 6. Intangible Assets and Goodwill Intangible Assets Our recognized intangible assets consist of patents and the unpatented technological know-how of Danimer Catalytic Technologies. Our legacy patents were initially recorded at cost. The values of Danimer Catalytic Technologies' patents and unpatented know-how are inseparable and represent their acquisition-date fair value, less subsequent amortization. We capitalize the costs of patent acquisition as well as the costs of the defense of patents when we believe a successful defense of that patent is probable and that a successful defense increases the value of the patent. Patent costs are amortized on a straight-line basis over their estimated useful lives, which range from 13 to 20 years. Our intangible portfolio has an estimated weighted average useful life of 19 years. Intangible assets, net, consisted of the following: June 30, December 31, (in thousands) 2022 2021 Intangible assets, gross $ 93,447 $ 93,244 Capitalized patent costs not yet subject to amortization 1,003 869 Intangible assets subject to amortization, gross 92,444 92,375 Accumulated amortization, beginning balance ( 8,585 ) ( 6,496 ) Amortization in the quarter ended: March 31 ( 1,181 ) ( 124 ) June 30 ( 1,186 ) ( 125 ) September 30 - ( 657 ) December 31 - ( 1,183 ) Accumulated amortization, ending balance ( 10,952 ) ( 8,585 ) Intangible assets subject to amortization, net 81,492 83,790 Total intangible assets, net $ 82,495 $ 84,659 We report amortization expense primarily in research and development expense. Goodwill Goodwill is tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis each November 1 st and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. As a result of the continuation of our sustained market capitalization level below our book equity value, we noted that there were indicators that an impairment loss may have occurred. We performed an interim qualitative impairment assessment related to the triggering event noted above, and determined that it was more likely than not that our goodwill and long-lived assets were not impaired. Changes in the carrying amount of goodwill were as follows: June 30, (in thousands) 2022 Balance at beginning of period $ 62,649 Adjustment of estimate of fair value of liabilities assumed related to Danimer Catalytic Technologies acquisition 14 Balance at end of period $ 62,663

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2022
Accounts Payable and Accrued Liabilities [Abstract]
Accrued Liabilities	Note 7. Accrued Liabilities The components of accrued liabilities were as follows: June 30, December 31, (in thousands) 2022 2021 Construction in progress accruals $ 3,225 $ 8,896 Compensation and related expenses 2,235 4,572 Accrued taxes 1,068 500 Accrued loss on supply contract 689 1,423 Legal settlement 625 1,250 Accrued utilities 482 320 Accrued interest 395 274 Accrued consulting fees 344 55 Transaction costs and other legal fees 467 850 Other 1,464 637 Total accrued liabilities $ 10,994 $ 18,777

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 8. Income Taxes Income tax expense for the three and six months ended June 30, 2022 was a benefit of $0.2 million and $0.5 million , respectively. Our effective income tax rates were 0.78 % and 0.93 % for the three and six months ended June 30, 2022, respectively. Our effective tax rate differed from the federal statutory rate of 21% due to our substantial valuation allowance against our deferred tax assets. Our effective income tax rate was zero for the three and six months ended June 30, 2021. In assessing the realizability of deferred income tax assets, we consider whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods at which time those temporary differences become deductible. In making valuation allowance determinations, we consider all available evidence, positive and negative, affecting specific deferred tax assets, including the scheduled reversal of deferred income tax liabilities, projected future taxable income, the length of carry-back and carry-forward periods, and tax planning strategies in making this assessment. On June 30, 2022 we continued to maintain a partial valuation allowance against our net deferred tax assets due to the uncertainty surrounding realization of such assets.

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Disclosure Text Block [Abstract]
Operating Leases	Note 9. Leases The following table sets forth the allocation of our operating lease costs. Three Months Ended June 30, Six Months Ended (in thousands) 2022 2021 2022 2021 Cost of revenue $ 626 $ 83 $ 1,254 $ 613 Selling, general and administrative 137 ( 91 ) 263 ( 40 ) Research and development 111 144 244 288 Total operating lease cost $ 874 $ 136 $ 1,761 $ 861

Private Warrants

Private Warrants	6 Months Ended
	Jun. 30, 2022
Text Block [Abstract]
Private Warrants	Note 10. Private Warrants At June 30, 2022 and December 31, 2021, there were 3,914,525 outstanding Private Warrants to purchase shares of our common stock at an exercise price of $ 11.50 per share, subject to adjustments, which were privately placed prior to the Business Combination. The Private Warrants are exercisable at any time after May 7, 2021 . On December 28, 2025 , any then outstanding Private Warrants will expire. The Private Warrants meet the definition of derivative instruments and are reported as liabilities at their fair values at each period end, with changes in the fair value of the Private Warrants recorded as a non-cash charge or gain. A rollforward of the Private Warrants liability is below. (in thousands) Balance at December 31, 2021 $ ( 9,578 ) Gain on remeasurement of private warrants 4,995 Balance at March 31, 2022 ( 4,583 ) Gain on remeasurement of private warrants 2,012 Balance at June 30, 2022 $ ( 2,571 )

Debt

Debt	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Long-Term Debt	Note 11. Debt The components of long-term debt were as follows: June 30, December 31, (in thousands) 2022 2021 3.25 % Convertible Senior Notes $ 240,000 $ 240,000 New Market Tax Credit Transactions 21,000 21,000 Subordinated Term Loan 10,205 10,205 Commercial Premium Finance Note 2,092 - Vehicle and Equipment Notes 419 407 Mortgage Notes 232 242 Asset-based Lending Arrangement - - Total $ 273,948 $ 271,854 Less: Total unamortized debt issuance costs ( 9,674 ) ( 10,563 ) Less: Current maturities of long-term debt ( 2,242 ) ( 357 ) Total long-term debt $ 262,032 $ 260,934 3.25% Convertible Senior Notes On December 21, 2021, we issued $ 240 million principal amount of our 3.250% Convertible Senior Notes due 2026 (“Notes”), subject to an indenture. The Notes are our senior, unsecured obligations and accrue interest at a rate of 3.250 % per annum, payable semi-annually in arrears on June 15 and December 15 of each year, beginning on June 15, 2022. The terms of the Notes are complex and can be found in greater detail in our Annual Report for the year ended December 31, 2021. We will settle the Notes by paying or delivering, as applicable, cash, shares of common stock or a combination of cash and shares, at our election. The initial conversion rate, which is subject to change, is approximately $ 10.79 per share of common stock. If certain liquidity conditions are met, we may redeem the Notes between December 19, 2024, and October 20, 2026. The Notes will mature on December 15, 2026. Capped Calls Also in December 2021, in connection with the Notes, we purchased capped calls (“Capped Calls”) with certain well-capitalized financial institutions for $ 35 million. The Capped Calls are call options that permit us, at our option, to require the counterparties to deliver to us shares of our common stock. We may also net-settle the Capped Calls and receive cash instead of shares. The Capped Calls are indexed to our own common stock and qualify for equity classification and have no effect on operating results. We have not exercised any of the Capped Calls at June 30, 2022, and the Capped Calls expire on April 12, 2027 . Asset-based Lending Arrangement On April 29, 2021, we entered into a credit facility (“Credit Agreement”), which we amended December 15, 2021, with Truist Bank that includes a $ 20.0 million variable interest rate asset-based lending arrangement. The amount of the revolving commitment available for borrowing at any given time is subject to a borrowing base formula that is based upon our qualifying accounts receivable and inventory. Any borrowings are secured by these assets. These arrangements mature on April 29, 2026 . Interest on any borrowings is payable monthly and is calculated, at our election, using either a base rate (as defined in the Credit Agreement) plus an applicable margin of 1.50 % for revolving loans and 1.75 % for equipment loans, or a LIBOR market index rate (“LMIR”) (as defined in the Credit Agreement) plus an applicable margin of 2.50 % for revolving loans and 2.75 % for equipment loans. If we maintain a trailing twelve month consolidated fixed charge coverage ratio (as defined in the Credit Agreement) of 1.1:1.0 or better and no event of default exists, then the applicable margins for base rate revolving loans and LMIR rate loans are 1.00 % and 2.00 %, respectively. The Credit Agreement contains customary affirmative and negative covenants, and after October 29, 2023, we are required to maintain a trailing twelve month consolidated fixed charge coverage ratio of at least 1.1:1.0. At June 30, 2022, we had no borrowings outstanding under the Credit Agreement and estimated that we had no availability under this arrangement. As also disclosed in Note 16, on August 5, 2022, we entered into an agreement with Truist Bank to pay off our existing Credit Agreement and terminate Truist’s lending obligations thereunder. Given the restrictive covenants contained in the Credit Agreement, this facility did not provide sufficient liquidity to justify the ongoing costs of maintaining it. We expect to incur a loss on early extinguishment of debt in the quarter ending September 30, 2022 in connection with the write off of $ 1.4 million of unamortized debt issuance costs. Subordinated Term Loan In March 2019, we, through a subsidiary, entered into a subordinated second credit agreement (“Subordinated Term Loan”) for $ 10 million in term loans. The term loans mature on February 13, 2024 and require monthly interest only payments, with the outstanding principal balance due at maturity. The Subordinated Term Loan provides for “springing” financial covenants including a maximum capital expenditures limit, leverage ratio, fixed charge coverage ratio and adjusted EBITDA covenants, certain of which became more restrictive over time, and which do not apply as long as the borrowing subsidiary maintains an unrestricted cash deposit of at least $ 10 million. The Subordinated Term Loan remains secured by all real and personal property of the borrowing subsidiary and its subsidiaries but is subordinated to all other existing lenders. At June 30, 2022, we were in compliance with all financial covenants. New Markets Tax Credit Transactions We entered into financing arrangements under the New Markets Tax Credit (“NMTC”) program during 2019 with various unrelated third-party financial institutions (individually and collectively referred to as “Investors”), which then invest in certain "Investment Funds. In each of the financing arrangements, we loaned money to the Investment Funds. These loans of $ 13.4 million are recorded as leveraged loan receivables as of June 30, 2022 and December 31, 2021. Each Investment Fund then contributed the funds from our loan and the Investor’s investment to a special purpose entity, which then in turn loaned the contributed funds to a wholly owned subsidiary of the Company. We expect these borrowings, and our related loans to the Investment Funds, will be forgiven in 2026. Commercial Premium Finance Note In June 2022, we entered into a financing agreement related to premiums of certain insurance policies. This note bears interest at 3.99 % with a maturity date of June 2023. Vehicle and Equipment Notes We have seventeen vehicle and equipment notes outstanding at June 30, 2022 primarily relating to motor vehicles and warehouse equipment. We make monthly payments on these notes at interest rates ranging from 5.11 % to 8.49 %. Mortgage Notes We have two mortgage notes secured by residential property. These notes bear interest at 6.5 % and 5.25 % with maturity dates in October 2023 and March 2025 .

Equity

Equity	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Equity	Note 12. Equity Common Stock The following table summarizes the common stock activity for the three and six months ended June 30, 2022 and 2021, respectively. Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Balance, beginning of period 100,760,215 85,339,145 100,687,820 84,535,640 Issuance of common stock 354,646 12,392,934 427,041 13,196,439 Balance, end of period 101,114,861 97,732,079 101,114,861 97,732,079 Public Warrants At December 31, 2020 , there were 10 million outstanding publicly traded warrants to purchase shares of our common stock with an exercise price of $ 11.50 per share, subject to adjustments (“Public Warrants”). The Public Warrants were exercisable and potentially redeemable after May 7, 2021. On June 16, 2021, we redeemed 50,965 Public Warrants, which included all unexercised Public Warrants. Prior to the redemption, 12,033,169 Public Warrants, including some Public Warrants that had initially been Private Warrants, were exercised. Net of fees, we collected $ 138.1 million in connection with these exercises and redemptions. The Public Warrants had qualified as equity instruments and we had included them in additional paid-in capital. Non-Plan Legacy Danimer Options and Warrants Prior to 2017, Legacy Danimer had issued 208,183 stock options that were not a part of either the 2016 Executive Plan or the 2016 Omnibus Plan. These options had a weighted average exercise price of $ 30 per share. On December 29, 2020, the then-remaining 30,493 of these options were converted to options to purchase 279,255 shares of our common stock with a weighted average exercise price of $ 3.28 per share. During 2021, 153,763 of these options were exercised and as of June 30, 2022, 125,489 of these options remain. As of December 29, 2020, Legacy Danimer had 55,319 warrants outstanding with an exercise price of $ 30 per share. In connection with the Business Combination, these options were converted to options to purchase 506,611 shares of our common stock with an exercise price of $ 3.28 per share. All remaining Legacy Danimer warrants were exercised during the three month period ended March 31, 2021 on a cashless basis by issuing 435,961 shares of common stock. Anti-dilutive Instruments The following instruments were excluded from the calculation of diluted shares outstanding because the effect of including them would have been anti-dilutive. Three Months Ended June 30, Six Months Ended June 30,  2022  2021 2022  2021 Convertible debt 22,250,040  - 22,250,040  - Employee stock options 11,439,142  37,500 11,439,142  10,682,969 Private Warrants 3,914,525  - 3,914,525  3,915,863 Restricted shares 2,671,482 - 2,671,482 3,035,676 Performance shares 50,251 - 50,251 - Legacy Danimer options 125,489  - 125,489  125,490 Total excluded instruments 40,450,929 37,500 40,450,929 17,759,998

Revenue

Revenue	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Note 13. Revenue We evaluate financial performance and make resource allocation decisions based upon the results of our single operating and reportable segment; however, we believe presenting revenue split between our primary revenue streams of products and services best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors. We generally produce and sell finished products, for which we recognize revenue upon shipment. Due to the highly specialized nature of our products, returns are infrequent, and therefore we do not estimate amounts for sales returns and allowances. There are no forms of variable consideration such as discounts, rebates, or volume discounts that we estimate to reduce our transaction price. We defer certain contract fulfillment costs. These costs are amortized to cost of revenue on a per-pound basis as we sell the related product. During the three months ended June 30, 2022 and 2021, we charged $ 0.1 million of fulfillment costs to cost of revenue. During the six months ended June 30, 2022 and 2021, we charged $ 0.3 million of fulfillment costs to cost of revenue. At June 30, 2022 and December 31, 2021 we had recorded gross contract assets of $ 2.9 million and $ 2.5 million, respectively, related to these fulfillment costs. Our R&D services contract customers generally pay us at the commencement of the agreement and then at additional intervals as outlined in each contract. We recognize contract liabilities for such payments and then recognize revenue as we satisfy the related performance obligations. To the extent collectible revenue recognized under this method exceeds the consideration received, we recognize contract assets for such unbilled consideration. The following table shows the significant changes in the R&D contract asset and contract liability balances. June 30, December 31, (in thousands) Contract Assets Contract Liabilities Contract Assets Contract Liabilities Beginning balance $ 2,128 $ ( 214 ) $ - $ ( 2,115 ) Revenue recognized in the quarter ended: March 31 ( 582 ) 582 - 1,397 June 30 2,038 210 1,530 1,513 September 30 - - 6 572 December 31 - - 592 675 Total revenue recognized 1,456 792 2,128 4,157 Unearned consideration received in the quarter ended: March 31 - ( 368 ) - ( 1,600 ) June 30 ( 50 ) ( 2,500 ) - - September 30 - - - - December 31 - - - ( 656 ) Total unearned consideration received ( 50 ) ( 2,868 ) - ( 2,256 ) Reserves recorded in the quarter ended: June 30 ( 1,215 ) - - - Ending balance $ 2,319 $ ( 2,290 ) $ 2,128 $ ( 214 ) COVID-related shutdowns have caused significant delays in production trials and material testing at outside laboratories, which resulted in missing the deadlines specified in one of our contract R&D arrangements. During the three months ended June 30, 2022, our partner in this project elected to cancel it, according to the terms of the contract, due to these delays. As a result, we recorded a reserve of $ 1.2 million against the outstanding contract asset. Disaggregated Revenues Revenue by geographic areas is based on the location of the customer. The following is a summary of revenue information by major geographic area: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Domestic $ 11,540 $ 10,457 $ 22,221 $ 19,419 Germany - 921 2,689 2,176 Belgium 556 1,328 1,084 2,505 Switzerland ( 223 ) 1,535 80 2,761 All other countries 830 230 1,372 791 Total revenues $ 12,703 $ 14,471 $ 27,446 $ 27,652

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Note 14. Stock-Based Compensation We grant various forms of stock-based compensation, including restricted stock units, stock options and performance-based restricted stock units under our Danimer Scientific, Inc. 2020 Long-Term Equity Incentive Plan (“2020 Incentive Plan”) and employee stock purchase plan instruments under our 2020 Employee Stock Purchase Plan (“2020 ESPP”). We also have outstanding employee and director stock options that had been issued prior to the Business Combination under legacy stock plans. The 2020 Incentive Plan provides for the grant of stock options, stock appreciation rights, and full value awards. Full value awards include restricted stock, restricted stock units, deferred stock units, performance stock and performance stock units. In connection with the acquisition of Novomer, Inc. described in Note 2, we obtained additional authorized share pool of 289,951 shares, which could only be granted to former Novomer, Inc. employees or employees hired after August 11, 2021, of which no shares remain at June 30, 2022. On January 16, 2022, our Board approved the assumption of the remaining authorized but unissued 2,895,411 shares under the Legacy Danimer 2016 Executive Plan and 2016 Omnibus Plan into our 2020 Incentive Plan. On June 30, 2022 and December 31, 2021, 1,736,571 shares and 213,997 shares, respectively, of our common stock remained authorized for issuance with respect to awards under the 2020 Incentive Plan. The 2020 ESPP Plan provides for the sale of our common stock to our employees through payroll withholding at a discount of 15 % from the lower of the closing price of our common stock on the first or last day of each biannual offering period. Up to 2,571,737 shares of our common stock were authorized to be issued under this plan. We have issued 83,180 shares as of June 30, 2022. These share pool limits are subject to adjustment in the event of a stock split, stock dividend or other changes in our capitalization. The following table sets forth the allocation of our stock-based compensation expense. Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Cost of revenue $ 10 $ 28 $ 39 $ 53 Selling, general and administrative 12,707 12,245 24,572 18,026 Research and development 1,830 1,758 3,634 2,617 Total stock-based compensation $ 14,547 $ 14,031 $ 28,245 $ 20,696 Restricted Shares During the three months ended March 31, 2022, we granted 38,659 restricted shares that lapse on February 7, 2023 and 103,092 restricted shares that lapse on successive thirds of the award on February 7, 2023, 2024 and 2025, respectively. We recognize the compensation expense for these shares on a straight-line basis from the grant date through February 7, 2025. During the three months ended March 31, 2021, we granted 1,517,836 restricted shares. The restrictions on these shares lapse on successive thirds of the award on December 29, 2021, 2022 and 2023, respectively, and 505,944 of these shares vested during 2021. We recognize the compensation expense for these shares on a straight-line basis from the grant date through December 29, 2023. We recognized $ 4.8 million and $ 5.0 million of expense related to these awards during the three months ended June 30, 2022 and 2021, respectively, and $ 9.5 million and $ 6.2 million during the six months ended June 30, 2022 and 2021, respectively. We did no t issue any restricted shares for the three months ended June, 30, 2022 or June 30, 2021. At June 30, 2022, 1,153,642 shares remained outstanding. Also during the three months ended March 31, 2021, we granted 1,517,840 restricted shares for which the restrictions lapse on successive thirds of the award on the first date the volume-weighted average price per share of our common stock equals or exceeds $ 24.20 for any 20 trading dates within 30-day trading periods beginning on December 29, 2021, 2022, and 2023, respectively. We are recognizing the compensation expense for these shares on a straight-line basis from the grant date through January 2024. We recognized $ 4.6 million and $ 4.8 million of expense during the three months ended June 30, 2022 and 2021, respectively, and $ 9.2 million and $ 6.0 million during the six months ended June 30, 2022 and 2021, respectively. We did no t issue any restricted shares for the three months ended June, 30, 2022 or June 30, 2021.All of these shares remained outstanding at June 30, 2022. Performance Shares On March 31, 2022, we awarded 489,949 shares of restricted stock with performance conditions. These shares are unvested until attainment of performance targets defined in the grant agreement as follows: • 30% of the shares are subject to a total PHA revenue metric based on 2024 financial results. 50% of these shares vest if total PHA revenue is $151 million, 100% vest if total PHA revenue is $189 million or higher, with prorated vesting between $ 151 million and $ 189 million. • 30% of the shares are subject to an Adjusted EBITDA metric based on 2024 financial results. 50% of these shares vest if Adjusted EBITDA is $9.2 million, 100% vest if Adjusted EBITDA is $13.8 million or higher, with prorated vesting between $ 9.2 million and $ 13.8 million. • 40% of the shares are subject to a Neat PHA production capacity metric based on a third party assessment at December 31, 2024, 50% of the shares vest if capacity is 68 million pounds, 100% vest if capacity is 81 million pounds or higher, with prorated vesting between 68 million pounds and 81 million pounds. On July 23, 2021, we awarded 95,943 shares of restricted stock with performance conditions. These shares are unvested until attainment of performance targets defined in the grant agreement as follows: • 30% of the shares are subject to a return on equity "ROE" metric based on 2023 financial results. 50% of these shares vest if ROE is 5%, 100% vest if ROE is 9% or higher, with prorated vesting between 5 % and 9 %. • 3 0% of the shares are subject to an EBITDA metric based on 2023 financial results. 50% of these shares vest if EBITDA is $ 45 million, 100% vest if EBITDA is $ 65 million or higher, with prorated vesting between $ 45 million and $ 65 million. • 40% of the shares are subject to a Neat PHA production capacity metric based on a third party assessment at December 31, 2023, 50% of the shares vest if capacity is 75 million pounds, 100% vest if capacity is 90 million pounds or higher, with prorated vesting between 75 million pounds and 90 million pounds. In addition to these performance conditions, vesting of certain of these shares is also subject to having sufficient capacity in the 2020 Incentive Plan, which may not have enough shares remaining to fulfill these awards. In the event registered shares are unavailable, 535,641 of the 585,892 outstanding performance shares must be settled in cash as calculated using the price of our common stock on the vesting date. Due to this cash settlement feature, certain performance shares are accounted for as a liability that is marked to market using the price of our common stock at the end of each reporting period, with a life-to-date expense adjustment. At June 30, 2022, the long-term liability for these performance shares was $ 0.3 million. During the three and six months ended June 30, 2022, we recognized related expense of $ 0.2 million and $ 0.3 million, respectively, included in selling, general and administrative expenses. Other than this mark to market effect, expense is recognized on a straight-line basis between the dates of grant and the vesting dates, which we anticipate will be in February 2024 and March 2025, respectively. We did no t issue any performance shares for the three months ended June 30, 2022 or June 30, 2021. All of these performance shares remained outstanding at June 30, 2022. Stock Options A summary of share-settled stock option activity under our equity plans is as follows:   Number of Options  Weighted Average Exercise Price  Weighted Average Remaining Contractual Term (Years)  Aggregate Intrinsic Value Balance, December 31, 2021 10,589,010 $ 14.85 7.39 $ 22,473,835 Granted 688,240 $ 3.96 Exercised ( 50,000 ) $ 3.28 $ 81,300 Balance, March 31, 2022  11,227,250  $ 14.24 7.32 $ 11,642,645 Granted 221,892 $ 4.07 Exercised ( 10,000 ) $ 3.28 $ 18,300 Balance, June 30, 2022 11,439,142 $ 14.05 7.13 $ 5,637,529 Exercisable  4,473,003 $ 4.84 4.77 $ 5,114,474 Vested and expected to vest  11,439,142 $ 14.05 7.13 $ 5,637,529 The aggregate intrinsic values are calculated as the difference between the exercise price of the indicated stock options and the fair value of our common stock on the respective exercise dates or on June 30, 2022, as applicable. During the quarter ended March 31, 2022, we also granted 972,222 stock options that contained a cash-settlement feature if adequate shares were not available to settle the award by the vesting dates. During 2021, we granted 1,710,947 options that vest ratably on the three successive anniversaries of the grant date with the same cash-settlement feature. For the three and six months ended June 30, 2022, we recognized expense of $ 0.2 million and $ 0.3 million, respectively, and recorded a long-term liability of $ 0.4 million at June 30, 2022 related to these stock options. There were no stock options issued with a cash settlement feature during the three months ended June 30, 2022. The weighted average grant-date fair values of options granted during the three month period ended June 30, 2022 was $ 1.84 . There were no options granted during the three month period ended June 30, 2021. During the three month period ended March 31, 2022 and March 31, 2021 the weighted average grant-date fair value of options granted were $ 1.77 and $ 18.52 , respectively. As of June 30, 2022, there was $ 90.6 million of unrecognized compensation cost related to unvested stock options and restricted shares granted under the 2020 Incentive Plan. That cost is expected to be recognized over a weighted-average period of 2.7 years.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15. Commitments and Contingencies Commitments In connection with our 2007 acquisition of certain intellectual property, we agreed to pay royalties upon production and sale of PHA. The royalty is $ 0.05 per pound for the first 500 million pounds of PHA sold and decreases to $ 0.025 per pound for cumulative sales in excess of that amount until the underlying patents expire. We incurred approximately $ 0.2 million in royalties during each of the six months ended June 30, 2022 and 2021. We have open purchase orders related to our Kentucky Facility Phase II expansion and our Greenfield plant construction totaling $ 90.6 million with anticipated delivery at various dates through December 2024. In November 2015, we terminated a former executive and terminated our contract with an advisory firm (“Advisory Contract”), pursuant to which we, through the advisory firm, engaged the individual as an executive of the Company. In December 2015, we deemed the Advisory Contract, together with all related arrangements in connection therewith, void, including any share issuances in connection with such arrangements. We filed suit against the former executive and the advisory firm during 2016, and various counterclaims were filed by the former executive and the advisory firm. During the third quarter of 2020, this matter was settled, we agreed to pay $8 million to resolve all outstanding claims, the executive agreed to the cancellation of any shares issued to him pursuant to the Advisory Contract and related arrangements, and the parties exchanged of mutual releases. The remaining unpaid liabilities of $ 0.6 million and $ 1.25 million at June 30, 2022 and December 31, 2021, respectively, are included in accrued liabilities. Litigation Matters On May 14, 2021 a class action complaint was filed by Darryl Keith Rosencrants in the United States District Court for the Eastern District of New York, on May 18, 2021, a class action complaint was filed by Carlos Caballeros in the United States District Court for the Middle District of Georgia, on May 18, 2021 a class action complaint was filed by Dennis H. Wilkins also in the United States District Court for the Middle District of Georgia, and on May 19, 2021, a class action complaint was filed by Elizabeth and John Skistimas in the United States District Court for the Eastern District of New York. Each plaintiff or plaintiffs brought the action individually and on behalf of all others similarly situated against the Company. The alleged class varies in each case but covers all persons and entities other than Defendants who purchased or otherwise acquired our securities between October 5, 2020 and May 4, 2021 (“Class Period”). Plaintiffs are seeking to recover damages caused by Defendants’ alleged violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and Rule 10b-5 promulgated thereunder. The complaints are substantially similar and are each premised upon various allegations that throughout the Class Period, Defendants made materially false and misleading statements regarding, among other things, our business, operations and compliance policies. Plaintiffs seek the following remedies: (i) determining that the lawsuits may be maintained as class actions under Rule 23 of the Federal Rules of Civil Procedure, (ii) certifying a class representative, (iii) requiring Defendants to pay damages allegedly sustained by plaintiffs and the class members by reason of the acts alleged in the complaints, and (iv) awarding pre-judgment and post-judgment interest as well as reasonable attorneys’ fees, expert fees and other costs. On July 29, 2021, the Georgia court transferred the Georgia cases to New York, and all four class actions have been consolidated into a single lawsuit in the Eastern District of New York. On January 19, 2022, a Consolidated Amended Class Action Complaint (“Amended Complaint”) was filed in the Eastern District of New York, naming as defendants the Company, its directors and certain of its officers as well as certain former directors (collectively, “Defendants”). The Amended Complaint is brought on behalf of a class consisting of (i) purchasers of shares of the Company during the period October 5, 2020 to May 4, 2021, (ii) all holders of the Company’s Class A common stock entitled to vote on the merger transaction between the Company and Meredian Holdings Group, Inc. consummated on December 28, 2020 and (iii) purchasers of Company securities pursuant to the Company’s Registration Statement on Form S-4 that was declared effective on December 16, 2020 or the Company’s Registration Statement on Form S-1 that was declared effective on February 16, 2021. The Amended Complaint asserts claims for violations of Sections 10(b), 14(a) and 20(a) of the Exchange Act and Rules 10(b)-5(a)-(c) promulgated thereunder and Sections 11, 12 and 15 of the Securities Act of 1933, as amended (the “Securities Act”). Plaintiffs seek the following remedies: (a) a determination that the lawsuit is a proper class action pursuant to Rule 23 of the Federal Rules of Civil Procedure and certifying Plaintiffs as class representative, (b) awarding compensatory and punitive damages allegedly sustained by the class members by reason of the acts set forth in the Amended Complaint and (c) awarding pre-judgment and post-judgment interest and costs and expenses, including reasonable attorneys’ fees and experts’ fees and other costs. The Defendants filed a motion to dismiss the Amended Complaint on May 20, 2022. Plaintiffs served their opposition papers to the motion to dismiss on July 21, 2022 , and Defendants’ reply is due by September 6, 2022. In their opposition papers, Plaintiffs have now confirmed that, based on Defendants’ arguments in the motion to dismiss, Plaintiffs have dropped seven of the nine counts, eliminating all of the Securities Act counts specifically relating to the proxy solicitation, registration statements and related control person claims, and all that now remains are the first two counts under Rules 10(b)-5(a)-(c) of the Exchange Act and control person liability. Additionally, all of the Defendants other than Danimer and three of its current or former officers or directors have been dismissed from the case. On May 24, 2021, a shareholder derivative lawsuit was filed in the Court of Chancery of the State of Delaware by Richard Delman on behalf of the Company, alleging breach of fiduciary duty against the Company’s directors. On October 6, 2021, a shareholders derivative lawsuit was filed in the United States District Court for the District of Delaware by Ryan Perri on behalf of the Company, alleging breach of fiduciary duty against the Company’s directors. Both derivative lawsuits have been stayed pending the outcome of Defendants’ motion to dismiss the securities class actions. These derivative complaints repeat certain allegations which are already in the public domain. Defendants deny the allegations of the above complaints, believe the lawsuits are without merit and intend to defend them vigorously. Since we are unable to estimate the likelihood of incurring a loss, or the amount of loss, if any, related to these matters, we have not accrued any losses for these matters at June 30, 2022. On May 5, 2021, we received a letter from the Atlanta regional office of the SEC, in connection with a non-public, fact-finding inquiry, requesting that we voluntarily produce certain specified information. On July 14, 2021, we timely and voluntarily produced the information requested by the SEC. On January 26, 2022, we received a follow-up request from the SEC for additional documents and information. By April 8, 2022, we timely and voluntarily produced the additional information requested by the SEC. On June 27, 2022, we received a follow-up request from the SEC for additional information. By August 5, 2022, we timely and voluntarily produced such additional information requested by the SEC as we were able to provide. In the ordinary course of business, we may be a party to various other legal proceedings from time to time.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 16. Subsequent Events As also disclosed in Note 11, on August 5, 2022, we entered into an agreement with Truist Bank to pay off our existing Credit Agreement and terminate Truist’s lending obligations thereunder. Given the restrictive covenants contained in the Credit Agreement, this facility did not provide sufficient liquidity to justify the ongoing costs of maintaining it. We expect to incur a loss on early extinguishment of debt in the quarter ending September 30, 2022 in connection with the write off of $ 1.4 million of unamortized debt issuance costs.

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2022
Business Combinations [Abstract]
Schedule of Preliminary Fair Values of Assets Acquired And Liabilities Assumed	The table below sets forth the preliminary fair values of assets acquired and liabilities assumed including the adjustments recorded in the six months ended June 30, 2022: December 31, June 30, (in thousands) 2021 Adjustments 2022 Cash and restricted cash $ 2,741 $ - $ 2,741 Property, plant and equipment 18,622 - 18,622 Other assets acquired 2,302 - 2,302 Right-of-use asset 2,715 - 2,715 Acquired technology 84,400 - 84,400 Goodwill 62,649 14 62,663 Deferred tax liability ( 14,246 ) - ( 14,246 ) Lease liability ( 2,759 ) - ( 2,759 ) Liabilities assumed ( 2,004 ) ( 14 ) ( 2,018 ) Contingent purchase price payable ( 500 ) - ( 500 ) Total preliminary purchase price $ 153,920 $ - $ 153,920
Summary of Proforma Adjustments	The following includes pro forma adjustments to reflect amortization of acquired technology intangible assets. We do not disclose pro forma impact related to income taxes or earnings-per-share as we do not believe those are useful to the reader in our situation. Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Revenue $ 12,703 $ 14,492 $ 27,446 $ 27,687 Loss from operations ( 32,120 ) ( 23,921 ) ( 62,809 ) ( 40,193 )

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Considerations [Abstract]
Schedule of ranges of values used and fair value determined	The following table sets forth the fair values we calculated and the ranges of values used in our Black Scholes calculations for stock options, other than ESPP awards. June 30, Three Months Ended June 30, 2022 2022 2021 Share prices of our common stock $ 4.56 $ 4.04 - $ 4.56 $ 15.89 - $ 38.33 Expected volatilities 47.05 % 45.72 % - 47.39 % 41.50 % - 41.50 % Risk-free rates of return 2.97 % 2.81 % - 2.98 % 1.05 % - 1.05 % Expected option terms (years) 5.28 5.06 - 6.00 6.00 - 6.00 Calculated option values $ 1.05 $ 0.33 - $ 2.32 $ 18.52 - $ 18.52 The table below sets forth the inputs we used in our Black Scholes models for Private Warrants valuations and the fair values determined. June 30, December 31, 2021 Share price of our common stock $ 4.56 $ 8.52 Expected volatility 50.9 % 47.6 % Risk-free rate of return 2.95 % 1.11 % Expected warrant term (years) 3.50 3.99 Fair value determined per warrant $ 0.66 $ 2.45

Inventories, net (Tables)

Inventories, net (Tables)	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories, net consisted of the following: June 30, December 31, (in thousands) 2022 2021 Raw materials $ 18,535 $ 11,555 Work in process 981 928 Finished goods and related items 13,213 12,090 Total inventories, net $ 32,729 $ 24,573

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property, plant, and equipment, net	Property, plant and equipment, net, consisted of the following: June 30, December 31, (in thousands) Estimated Useful Life (Years) 2022 2021 Land and improvements 20 $ 92 $ 92 Leasehold improvements Shorter of useful life or lease term 28,036 27,845 Buildings 15 - 40 2,156 2,156 Machinery and equipment 5 - 20 100,977 97,923 Motor vehicles 7 - 10 921 912 Furniture and fixtures 7 - 10 443 420 Office equipment 3 - 10 3,509 3,368 Construction in progress N/A 308,148 212,647 444,282 345,363 Accumulated depreciation and amortization ( 35,397 ) ( 29,182 ) Property, plant and equipment, net $ 408,885 $ 316,181
Schedule of depreciation and amortization expense	We reported depreciation and amortization expense (which included amortization of intangible assets) as follows: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Cost of revenue $ 2,289 $ 1,951 $ 4,517 $ 3,790 Selling, general and administrative 163 177 323 273 Research and development 1,876 83 3,748 248 Total depreciation and amortization expense $ 4,328 $ 2,211 $ 8,588 $ 4,311
Schedule of Construction in Progress	Construction in progress consists primarily of the early stages of construction of our Greenfield facility in Bainbridge, Georgia and the build-out of our facility in Winchester, Kentucky, as noted in the table below. June 30, December 31, Georgia $ 155,329 $ 83,660 Kentucky 150,016 128,289 New York 2,803 698 $ 308,148 $ 212,647

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets net	Intangible assets, net, consisted of the following: June 30, December 31, (in thousands) 2022 2021 Intangible assets, gross $ 93,447 $ 93,244 Capitalized patent costs not yet subject to amortization 1,003 869 Intangible assets subject to amortization, gross 92,444 92,375 Accumulated amortization, beginning balance ( 8,585 ) ( 6,496 ) Amortization in the quarter ended: March 31 ( 1,181 ) ( 124 ) June 30 ( 1,186 ) ( 125 ) September 30 - ( 657 ) December 31 - ( 1,183 ) Accumulated amortization, ending balance ( 10,952 ) ( 8,585 ) Intangible assets subject to amortization, net 81,492 83,790 Total intangible assets, net $ 82,495 $ 84,659
Schedule of Goodwill	Changes in the carrying amount of goodwill were as follows: June 30, (in thousands) 2022 Balance at beginning of period $ 62,649 Adjustment of estimate of fair value of liabilities assumed related to Danimer Catalytic Technologies acquisition 14 Balance at end of period $ 62,663

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Accounts Payable and Accrued Liabilities [Abstract]
Schedule of accrued liabilities	The components of accrued liabilities were as follows: June 30, December 31, (in thousands) 2022 2021 Construction in progress accruals $ 3,225 $ 8,896 Compensation and related expenses 2,235 4,572 Accrued taxes 1,068 500 Accrued loss on supply contract 689 1,423 Legal settlement 625 1,250 Accrued utilities 482 320 Accrued interest 395 274 Accrued consulting fees 344 55 Transaction costs and other legal fees 467 850 Other 1,464 637 Total accrued liabilities $ 10,994 $ 18,777

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure Text Block [Abstract]
Schedule of operating lease costs	The following table sets forth the allocation of our operating lease costs. Three Months Ended June 30, Six Months Ended (in thousands) 2022 2021 2022 2021 Cost of revenue $ 626 $ 83 $ 1,254 $ 613 Selling, general and administrative 137 ( 91 ) 263 ( 40 ) Research and development 111 144 244 288 Total operating lease cost $ 874 $ 136 $ 1,761 $ 861

Private Warrants (Tables)

Private Warrants (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Measurement Inputs and Valuation Techniques [Abstract]
Summary of Rollforward of Private Warrants Liability	A rollforward of the Private Warrants liability is below. (in thousands) Balance at December 31, 2021 $ ( 9,578 ) Gain on remeasurement of private warrants 4,995 Balance at March 31, 2022 ( 4,583 ) Gain on remeasurement of private warrants 2,012 Balance at June 30, 2022 $ ( 2,571 )

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of long-term debt	The components of long-term debt were as follows: June 30, December 31, (in thousands) 2022 2021 3.25 % Convertible Senior Notes $ 240,000 $ 240,000 New Market Tax Credit Transactions 21,000 21,000 Subordinated Term Loan 10,205 10,205 Commercial Premium Finance Note 2,092 - Vehicle and Equipment Notes 419 407 Mortgage Notes 232 242 Asset-based Lending Arrangement - - Total $ 273,948 $ 271,854 Less: Total unamortized debt issuance costs ( 9,674 ) ( 10,563 ) Less: Current maturities of long-term debt ( 2,242 ) ( 357 ) Total long-term debt $ 262,032 $ 260,934

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Summary of the common stock activity	The following table summarizes the common stock activity for the three and six months ended June 30, 2022 and 2021, respectively. Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Balance, beginning of period 100,760,215 85,339,145 100,687,820 84,535,640 Issuance of common stock 354,646 12,392,934 427,041 13,196,439 Balance, end of period 101,114,861 97,732,079 101,114,861 97,732,079
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following instruments were excluded from the calculation of diluted shares outstanding because the effect of including them would have been anti-dilutive. Three Months Ended June 30, Six Months Ended June 30,  2022  2021 2022  2021 Convertible debt 22,250,040  - 22,250,040  - Employee stock options 11,439,142  37,500 11,439,142  10,682,969 Private Warrants 3,914,525  - 3,914,525  3,915,863 Restricted shares 2,671,482 - 2,671,482 3,035,676 Performance shares 50,251 - 50,251 - Legacy Danimer options 125,489  - 125,489  125,490 Total excluded instruments 40,450,929 37,500 40,450,929 17,759,998

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2022
Disaggregation of Revenue [Abstract]
Schedule of changes in R&D contract asset and contract liability balance	The following table shows the significant changes in the R&D contract asset and contract liability balances. June 30, December 31, (in thousands) Contract Assets Contract Liabilities Contract Assets Contract Liabilities Beginning balance $ 2,128 $ ( 214 ) $ - $ ( 2,115 ) Revenue recognized in the quarter ended: March 31 ( 582 ) 582 - 1,397 June 30 2,038 210 1,530 1,513 September 30 - - 6 572 December 31 - - 592 675 Total revenue recognized 1,456 792 2,128 4,157 Unearned consideration received in the quarter ended: March 31 - ( 368 ) - ( 1,600 ) June 30 ( 50 ) ( 2,500 ) - - September 30 - - - - December 31 - - - ( 656 ) Total unearned consideration received ( 50 ) ( 2,868 ) - ( 2,256 ) Reserves recorded in the quarter ended: June 30 ( 1,215 ) - - - Ending balance $ 2,319 $ ( 2,290 ) $ 2,128 $ ( 214 )
Schedule of revenue information by major geographic area	Revenue by geographic areas is based on the location of the customer. The following is a summary of revenue information by major geographic area: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Domestic $ 11,540 $ 10,457 $ 22,221 $ 19,419 Germany - 921 2,689 2,176 Belgium 556 1,328 1,084 2,505 Switzerland ( 223 ) 1,535 80 2,761 All other countries 830 230 1,372 791 Total revenues $ 12,703 $ 14,471 $ 27,446 $ 27,652

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-based Payment Arrangement [Abstract]
Schedule of stock option activity under our equity plans	A summary of share-settled stock option activity under our equity plans is as follows:   Number of Options  Weighted Average Exercise Price  Weighted Average Remaining Contractual Term (Years)  Aggregate Intrinsic Value Balance, December 31, 2021 10,589,010 $ 14.85 7.39 $ 22,473,835 Granted 688,240 $ 3.96 Exercised ( 50,000 ) $ 3.28 $ 81,300 Balance, March 31, 2022  11,227,250  $ 14.24 7.32 $ 11,642,645 Granted 221,892 $ 4.07 Exercised ( 10,000 ) $ 3.28 $ 18,300 Balance, June 30, 2022 11,439,142 $ 14.05 7.13 $ 5,637,529 Exercisable  4,473,003 $ 4.84 4.77 $ 5,114,474 Vested and expected to vest  11,439,142 $ 14.05 7.13 $ 5,637,529
Schedule of share based compensation activity	The following table sets forth the allocation of our stock-based compensation expense. Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Cost of revenue $ 10 $ 28 $ 39 $ 53 Selling, general and administrative 12,707 12,245 24,572 18,026 Research and development 1,830 1,758 3,634 2,617 Total stock-based compensation $ 14,547 $ 14,031 $ 28,245 $ 20,696

Basis of Presentation (Addition

Basis of Presentation (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Description of Business and Basis of Presentation (Details) [Line Items]
Common stock, par value (in Dollars per share)	$ 0.0001		$ 0.0001		$ 0.0001
Restated [Member]
Description of Business and Basis of Presentation (Details) [Line Items]
Net loss and comprehensive (loss) income	$ 0	$ 0	$ 0	$ 0

Business Combination (Additiona

Business Combination (Additional Information) (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Aug. 11, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Business Combination (Details) [Line Items]
Net loss		$ (30,445)	$ 39,248	$ (56,831)	$ (55,486)
Right-of-use assets		19,133		19,133		$ 19,240
Amortization expense		$ 2,900		$ 5,800
Novomer Inc Member
Business Combination (Details) [Line Items]
Aggregate purchase price	$ 153,900

Business Combinations - Schedul

Business Combinations - Schedule of Preliminary Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Business Combinations [Abstract]
Cash and restricted cash	$ 2,741	$ 2,741
Property, plant and equipment	18,622	18,622
Other assets acquired	2,302	2,302
Right-of-use asset	2,715	2,715
Acquired technology	84,400	84,400
Goodwill	62,663	62,649
Deferred tax liability	(14,246)	(14,246)
Lease liability	(2,759)	(2,759)
Liabilities assumed	(2,018)	(2,004)
Contingent purchase price payable	(500)	(500)
Total preliminary purchase price	153,920	$ 153,920
Cash and restricted cash, adjustments	0
Property, plant and equipment, adjustments	0
Other assets acquired, adjustments	0
Right-of-use asset, adjustments	0
Acquired technology, adjustments	0
Goodwill, adjustments	14
Deferred tax liability, adjustments	0
Lease liability, adjustments	0
Liabilities assumed, adjustments	(14)
Contingent purchase price payable, adjustments	0
Total preliminary purchase price, adjustments	$ 0

Business Combinations - Summary

Business Combinations - Summary of Proforma Adjustments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Business Acquisition, Pro Forma Information [Abstract]
Revenue	$ 12,703	$ 14,492	$ 27,446	$ 27,687
Loss from operations	$ (32,120)	$ (23,921)	$ (62,809)	$ (40,193)

Fair Value Considerations (Addi

Fair Value Considerations (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Convertible Debt, Fair Value Disclosures	$ 186.1			$ 186.1
Weighted average grant-date fair value of options granted (in Dollars per share)		$ 1.77	$ 18.52	$ 1.84
Exercise price per (in Dollars per share)	$ 11.50			11.50
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining stock, closing price				4.56
Grant date fair value of stock granted	$ 0			$ 0

Fair Value Considerations - Sch

Fair Value Considerations - Schedule of ranges of values used and fair value determined (Details) - Black-Scholes [Member] - $ / shares	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Dec. 31, 2021
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share prices of our common stock	$ 4.56		$ 4.56
Expected volatility			47.05%
Expected Volatility Rate, Maximum	47.39%	41.50%
Expected Volatility Rate, Minimum	45.72%	41.50%
Risk-free rate of return			2.97%
Risk Free Interest Rate, Maximum	2.98%	1.05%
Risk Free Interest Rate, Minimum	2.81%	1.05%
Expected option term (years)			5 years 3 months 10 days
Stock Option [Member] | Danimer Black Sholes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Calculated option values, Minimum			$ 1.05
Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share prices of our common stock	$ 4.56	$ 38.33	4.56
Expected option term (years)	6 years	6 years
Stock Option [Member] | Maximum [Member] | Danimer Black Sholes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Calculated option values, Maximum	$ 2.32	$ 18.52
Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share prices of our common stock	$ 4.04	$ 15.89	4.04
Expected option term (years)	5 years 21 days	6 years
Stock Option [Member] | Minimum [Member] | Danimer Black Sholes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Calculated option values, Minimum	$ 0.33	$ 18.52
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share prices of our common stock	$ 4.56		$ 4.56	$ 8.52
Expected volatility			50.90%	47.60%
Risk-free rate of return			2.95%	1.11%
Expected option term (years)			3 years 6 months	3 years 11 months 26 days
Fair value determined per warrant			$ 0.66	$ 2.45

Inventories, net (Details) - Sc

Inventories, net (Details) - Schedule of inventory - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule of inventory [Abstract]
Raw materials	$ 18,535	$ 11,555
Work in progress	981	928
Finished goods and related items	13,213	12,090
Total inventories, net	$ 32,729	$ 24,573

Inventories, net (Additional In

Inventories, net (Additional Information) (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Inventory, Net [Abstract]
Finished neat PHA included in finished goods	$ 5.9	$ 5.6

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - Schedule of Property, plant, and equipment, net - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 444,282	$ 345,363
Accumulated depreciation and amortization	(35,397)	(29,182)
Property, plant and equipment, net	$ 408,885	316,181
Land and improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	20 years
Property and equipment, gross	$ 92	92
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 28,036	27,845
Estimated Useful Life	Shorter of useful life or lease term
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,156	2,156
Buildings [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	15 years
Buildings [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	40 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 100,977	97,923
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	20 years
Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 921	912
Motor vehicles [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years
Motor vehicles [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 443	420
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,509	3,368
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Construction-in-progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 308,148	$ 212,647

Property, Plant and Equipment_3

Property, Plant and Equipment (Details) - Schedule of depreciation and amortization expense - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Total depreciation and amortization expense	$ 4,328	$ 2,211	$ 8,588	$ 4,311
Cost of revenue [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Total depreciation and amortization expense	2,289	1,951	4,517	3,790
Selling, general, and administrative [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Total depreciation and amortization expense	163	177	323	273
Research & development [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Total depreciation and amortization expense	$ 1,876	$ 83	$ 3,748	$ 248

Property, Plant and Equipment,

Property, Plant and Equipment, net - Summary of Construction in Progress (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Construction in progress	$ 308,148	$ 212,647
Georgia [Member]
Property, Plant and Equipment [Line Items]
Construction in progress	155,329	83,660
Kentucky [Member]
Property, Plant and Equipment [Line Items]
Construction in progress	150,016	128,289
New York [Member]
Property, Plant and Equipment [Line Items]
Construction in progress	$ 2,803	$ 698

Property, Plant and Equipment_4

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, plant, and equipment includes capitalized interest	$ 9,300		$ 9,300		$ 5,700
Property, plant and equipment interest costs	$ 2,000	$ 50	$ 3,600	$ 300

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Additional Information) (Details)	6 Months Ended
	Jun. 30, 2022
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life	19 years
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	20 years
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	13 years

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Schedule of intangible assets net (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 93,447	$ 93,244
Capitalized patent costs not yet subject to amortization	1,003	869
Intangible assets subject to amortization, gross	92,444	92,375
Intangible assets subject to amortization, net	81,492	83,790
Total intagible assets, net	82,495	84,659
Beginning Balance
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	(8,585)	(6,496)
March 31 [Member]
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	(1,181)	(124)
June 30 [Member]
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	(1,186)	(125)
September 30 [Member]
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization		(657)
December 31 [Member]
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization		(1,183)
Ending Balance
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	$ (10,952)	$ (8,585)

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Schedule of goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 62,649
Acquisition of Novomer	14
Goodwill	$ 62,663

Accrued Liabilities (Details) -

Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule of accrued liabilities [Abstract]
Construction in progress expenditures	$ 3,225	$ 8,896
Compensation and related expenses	2,235	4,572
Accrued taxes	1,068	500
Accrued loss on supply contract	689	1,423
Legal settlement	625	1,250
Accrued Utilities	482	320
Accrued interest	395	274
Accrued consulting fees	344	55
Transaction costs and other legal fees	467	850
Other	1,464	637
Total accrued liabilities	$ 10,994	$ 18,777

Income Taxes (Additional Inform

Income Taxes (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Deferred income taxes			$ (531)
Effective tax rates	0.78%	0%	0.93%	0%

Leases (Details) - Schedule of

Leases (Details) - Schedule of operating lease costs - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	$ 874	$ 136	$ 1,761	$ 861
Cost of revenue [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	626	83	1,254	613
Selling, general and administrative [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	137	(91)	263	(40)
Research and development [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	$ 111	$ 144	$ 244	$ 288

Private Warrants (Details)

Private Warrants (Details) - $ / shares	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	3,914,525	3,914,525
Warrant price per share	$ 11.50
Class of Warrant or Right, Date from which Warrants or Rights Exercisable	May 07, 2021
Private Warrants
Class of Warrant or Right [Line Items]
Warrant price per share	$ 11.50	$ 11.50
Warrants and Rights Outstanding, Maturity Date	Dec. 28, 2025

Private Warrants - Summary of R

Private Warrants - Summary of Rollforward of Private Warrants Liability (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Balance		$ (9,578)		$ (9,578)
Gain on remeasurement of private warrants	$ (2,012)		$ (58,740)	(7,007)	$ 21,957
Balance	(2,571)			(2,571)
PrivateWarrantsMember
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Balance	(4,583)	(9,578)		(9,578)
Gain on remeasurement of private warrants	2,012	4,995
Balance	$ (2,571)	$ (4,583)		$ (2,571)

Debt (Details) - Schedule of lo

Debt (Details) - Schedule of long-term debt - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	$ 273,948	$ 271,854
Less: Total unamortized debt issuance costs	(9,674)	(10,563)
Less: Current maturities of debt issuance costs	(2,242)	(357)
Total long-term debt	262,032	260,934
Subordinated Term Loan [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	10,205	10,205
NMTC Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	21,000	21,000
Asset Backed Lending Arrangement [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	0	0
Convertible Debt Note [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	240,000	240,000
Vehicle and Equipment Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	419	407
Mortgage Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	232	242
Commercial Premium Finance Note [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	$ 2,092	$ 0

Debt Schedule of long-term debt

Debt Schedule of long-term debt - Parenthetical (Details)	Jun. 30, 2022
Convertible Debt Note [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Interest rate	3.25%

Debt (Details)

Debt (Details) $ / shares in Units, $ in Thousands				3 Months Ended			6 Months Ended
	Dec. 21, 2021 USD ($) $ / shares	Dec. 16, 2021 USD ($)	Apr. 29, 2021 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($) Numbers	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) Numbers	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2019 USD ($)
Long-Term Debt (Details) [Line Items]
Unamortized debt issuance costs					$ 9,674		$ 9,674		$ 10,563
Convertible Senior Notes Due Year	2026
Total Availability of Borrowings Outstanding							0
Accrued interest					395		395		274
Unrestricted cash on deposit					140,388		140,388		286,487
Leverage loans receivable					13,408		13,408		$ 13,408
Gain on forgiveness of debt								$ 2,604
Interest expense					652	$ 203	1,644	$ 352
Conversion price per share (in Dollars per share) | $ / shares	$ 10.79
Subsequent Event [Member]
Long-Term Debt (Details) [Line Items]
Debt issuance costs				$ 1,400
2019 Term Loan [Member]
Long-Term Debt (Details) [Line Items]
Maturity date										Feb. 13, 2024
Unrestricted cash on deposit					$ 10,000		$ 10,000
Subordinated term loan										$ 10,000
Senior Notes [Member]
Long-Term Debt (Details) [Line Items]
Convertible Senior Notes Issued	$ 240,000
Interest rate	3.25%
Convertible Debt Note [Member]
Long-Term Debt (Details) [Line Items]
Interest rate					3.25%		3.25%
Revolving Loans [Member]
Long-Term Debt (Details) [Line Items]
Debt instrument, basis spread on variable rate			1%
Revolving Loans [Member] | Base Rate [Member]
Long-Term Debt (Details) [Line Items]
Debt instrument, basis spread on variable rate			1.50%
Revolving Loans [Member] | LIBOR Market Index Rate [Member]
Long-Term Debt (Details) [Line Items]
Debt instrument, basis spread on variable rate			2.50%
Equipment Loans [Member] | Base Rate [Member]
Long-Term Debt (Details) [Line Items]
Debt instrument, basis spread on variable rate			1.75%
Equipment Loans [Member] | LIBOR Market Index Rate [Member]
Long-Term Debt (Details) [Line Items]
Debt instrument, basis spread on variable rate			2.75%
LIMR Loan [Member]
Long-Term Debt (Details) [Line Items]
Debt instrument, basis spread on variable rate			2%
Mortgage Notes [Member]
Long-Term Debt (Details) [Line Items]
Number Of Notes | Numbers					2		2
Debt Instrument, Maturity Date, Description							These notes bear interest at 6.5% and 5.25% with maturity dates in October 2023 and March 2025
Commercial Premium Finance Note Member
Long-Term Debt (Details) [Line Items]
Interest rate					3.99%		3.99%
Vehicle and Equipment Notes [Member]
Long-Term Debt (Details) [Line Items]
Number Of Notes | Numbers					17		17
Minimum [Member] | Mortgage Notes [Member]
Long-Term Debt (Details) [Line Items]
Interest rate					5.25%		5.25%
Minimum [Member] | Vehicle and Equipment Notes [Member]
Long-Term Debt (Details) [Line Items]
Interest rate					5.11%		5.11%
Maximum [Member] | Mortgage Notes [Member]
Long-Term Debt (Details) [Line Items]
Interest rate					6.50%		6.50%
Maximum [Member] | Vehicle and Equipment Notes [Member]
Long-Term Debt (Details) [Line Items]
Interest rate					8.49%		8.49%
Asset Backed Lending Arrangement [Member]
Long-Term Debt (Details) [Line Items]
Borrowing Outstanding, Amount					$ 0		$ 0
Interest rate formula, description			base rate (as defined in the Credit Agreement) plus an applicable margin of 1.50% for revolving loans and 1.75% for equipment loans, or a LIBOR market index rate (“LMIR”) (as defined in the Credit Agreement) plus an applicable margin of 2.50% for revolving loans and 2.75% for equipment loans. If we maintain a trailing twelve month consolidated fixed charge coverage ratio (as defined in the Credit Agreement) of 1.1:1.0 or better and no event of default exists, then the applicable margins for base rate revolving loans and LMIR rate loans are 1.00% and 2.00%, respectively.
Capped Call Options [Member]
Long-Term Debt (Details) [Line Items]
Purchase of capped call options		$ 35,000
Capped Calls Expire Date							Apr. 12, 2027
Truist bank [Member]
Long-Term Debt (Details) [Line Items]
Maturity date			Apr. 29, 2026
Truist bank [Member] | Asset Backed Lending Arrangement [Member]
Long-Term Debt (Details) [Line Items]
Line of credit facility maximum borrowing capacity			$ 20,000
Line of Credit Facility			$ 20,000

Equity - Summary of the common

Equity - Summary of the common stock activity (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Stockholders' Equity Note [Abstract]
Balance, beginning of period	100,760,215	85,339,145	100,687,820	84,535,640
Issuance of common stock	354,646	12,392,934	427,041	13,196,439
Balance, end of period	101,114,861	97,732,079	101,114,861	97,732,079

Equity (Details)

Equity (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended			6 Months Ended	12 Months Ended
	Jun. 16, 2021	Dec. 29, 2020	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2016
Stockholders' Equity (Details) [Line Items]
Proceeds from Warrant Exercises	$ 138.1
Outstanding warrants (in Shares)			3,914,525			3,914,525	3,914,525
Options issued			221,892	688,240
Number of shares, exercised			(10,000)	(50,000)
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 11.50			$ 11.50
Weighted Average Exercise Price, Exercised (in Dollars per share)			$ 3.28	$ 3.28
Public Warrants
Stockholders' Equity (Details) [Line Items]
Warrants And Rights Exercised	12,033,169
Warrants And Rights Redeemed	50,965
Outstanding warrants (in Shares)								10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 11.50
Legacy Danimer options
Stockholders' Equity (Details) [Line Items]
Options issued									208,183
Weighted Average Exercise Price of per share (in Dollars per share)		$ 30
Number of shares, exercised							153,763
Exercisable and remained outstanding ( in shares)		30,493
Conversion of Stock, Shares Issued		279,255
Number of options exercised remains						125,489
Weighted Average Exercise Price, Exercised (in Dollars per share)		$ 3.28
Legacy Danimer warrants
Stockholders' Equity (Details) [Line Items]
Outstanding warrants (in Shares)		55,319
Weighted Average Exercise Price of per share (in Dollars per share)								$ 3.28
Conversion of Stock, Shares Converted								506,611
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 30
Conversion of Stock, Shares Issued					435,961

Equity Antidilutive Securities

Equity Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	40,450,929	37,500	40,450,929	17,759,998
Convertible Debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	22,250,040	0	22,250,040	0
Employee Stock Option Member
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	11,439,142	37,500	11,439,142	10,682,969
Private Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,914,525	0	3,914,525	3,915,863
Restricted Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,671,482	0	2,671,482	3,035,676
Performance shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	50,251	0	50,251	0
Legacy Danimer options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	125,489	0	125,489	125,490

Revenue (Details)

Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Fulfillment costs to cost of revenue	$ 100	$ 100	$ 300	$ 300
Contract assets recorded related to fulfillment costs	2,900		2,900		$ 2,500
Reserves recorded	$ 1,200		$ 1,216

Revenue (Details) - Change in C

Revenue (Details) - Change in Contract Asset and Contract Liability Balance - USD ($) $ in Thousands	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Beginning balance, Contract Liabilities		$ (214)
Ending Balance, Contract Liabilities	$ (2,290)	(2,290)		$ (214)
Reserves recorded	(1,200)	(1,216)
Research and Development Project [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Beginning balance, Contract Liabilities		(214)	(2,115)	(2,115)
Revenue Recognized		792		4,157
Unearned consideration received		(2,868)		(2,256)
Ending Balance, Contract Liabilities	(2,290)	(2,290)		(214)
Beginning Balance, Contract Asset		2,128	$ 0	0
Revenue recognized		1,456		2,128
Unearned consideration received		(50)		0
Ending Balance, Contract Asset	$ 2,319	2,319		2,128
Research and Development Project [Member] | March 31 [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognized		582		1,397
Unearned consideration received		(368)		(1,600)
Revenue recognized		(582)		0
Unearned consideration received		0		0
Research and Development Project [Member] | June 30 [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognized		210		1,513
Unearned consideration received		(2,500)		0
Revenue recognized		2,038		1,530
Unearned consideration received		(50)		0
Reserves recorded		(1,215)
Research and Development Project [Member] | September 30 [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognized		0		572
Unearned consideration received		0		0
Revenue recognized		0		6
Unearned consideration received		0		0
Research and Development Project [Member] | December 31 [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognized		0		675
Unearned consideration received		0		(656)
Revenue recognized		0		592
Unearned consideration received		$ 0		$ 0

Revenue (Details) - Summary of

Revenue (Details) - Summary of Revenue Information by Major Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 12,703	$ 14,471	$ 27,446	$ 27,652
Domestic
Disaggregation of Revenue [Line Items]
Total revenue	11,540	10,457	22,221	19,419
GERMANY
Disaggregation of Revenue [Line Items]
Total revenue	0	921	2,689	2,176
BELGIUM
Disaggregation of Revenue [Line Items]
Total revenue	556	1,328	1,084	2,505
SWITZERLAND
Disaggregation of Revenue [Line Items]
Total revenue	(223)	1,535	80	2,761
All Other Countries
Disaggregation of Revenue [Line Items]
Total revenue	$ 830	$ 230	$ 1,372	$ 791

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended				6 Months Ended
	Jul. 23, 2021	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Jan. 16, 2022	Dec. 31, 2021
Stock-Based Compensation (Details) [Line Items]
Performance stock and performance stock units		354,646		12,392,934		427,041	13,196,439
Additional Authorized Shares Pool		289,951				289,951
Number of performance shares issued		0		0
Weighted average grant-date fair value of options granted (in Dollars per share)			$ 1.77		$ 18.52	$ 1.84
Additional Restricted Stock Shares Granted					1,517,840
Restricted stock shares			103,092
Number of Shares, Granted		221,892	688,240
Unrecognized compensation cost related to nonvested stock options grant (in Dollars)		$ 90,600				$ 90,600
Weighted-average over period						2 years 8 months 12 days
Selling, general and administrative		20,975		$ 19,079		$ 43,211	$ 29,199
Stock-based compensation expense						$ 27,983	20,696
Third anniversary [Member]
Stock-Based Compensation (Details) [Line Items]
Share prices of our common stock					$ 24.20
Common stock equals or exceeds (in Dollars per share)					$ 24.20
Restricted Stock [Member]
Stock-Based Compensation (Details) [Line Items]
Restrictions Shares Vested					505,944
Restricted stock shares			38,659
Number of Shares, Granted					1,517,836
Performance Shares [Member]
Stock-Based Compensation (Details) [Line Items]
Performance stock and performance stock units						585,892
Restricted stock shares			489,949
Long term liability		300				$ 300
Performance Shares [Member] | Selling, general and administrative [Member]
Stock-Based Compensation (Details) [Line Items]
Stock-based compensation expense		$ 200				300
Performance Shares [Member] | ROE [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting description	30% of the shares are subject to a return on equity "ROE" metric based on 2023 financial results. 50% of these shares vest if ROE is 5%, 100% vest if ROE is 9% or higher, with prorated vesting between 5% and 9%.
Performance Shares [Member] | ROE [Member] | Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting percentage	9%
Performance Shares [Member] | ROE [Member] | Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting percentage	5%
Performance Shares [Member] | EBITDA Metric [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting description	0% of the shares are subject to an EBITDA metric based on 2023 financial results. 50% of these shares vest if EBITDA is $45 million, 100% vest if EBITDA is $65 million or higher, with prorated vesting between $45 million and $65 million.		30% of the shares are subject to an Adjusted EBITDA metric based on 2024 financial results. 50% of these shares vest if Adjusted EBITDA is $9.2 million, 100% vest if Adjusted EBITDA is $13.8 million or higher, with prorated vesting between $9.2 million and $13.8 million.
Performance Shares [Member] | EBITDA Metric [Member] | Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 65,000		$ 13,800
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)	65,000		13,800
Performance Shares [Member] | EBITDA Metric [Member] | Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	45,000		9,200
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)	$ 45,000		$ 9,200
Performance Shares [Member] | Neat PHA Production Capacity Metric [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting description	40% of the shares are subject to a Neat PHA production capacity metric based on a third party assessment at December 31, 2023, 50% of the shares vest if capacity is 75 million pounds, 100% vest if capacity is 90 million pounds or higher, with prorated vesting between 75 million pounds and 90 million pounds.		40% of the shares are subject to a Neat PHA production capacity metric based on a third party assessment at December 31, 2024, 50% of the shares vest if capacity is 68 million pounds, 100% vest if capacity is 81 million pounds or higher, with prorated vesting between 68 million pounds and 81 million pounds.
Performance Shares [Member] | Neat PHA Production Capacity Metric [Member] | Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 90,000		$ 81,000
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)	90,000		81,000
Performance Shares [Member] | Neat PHA Production Capacity Metric [Member] | Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	75,000		68,000
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)	$ 75,000		$ 68,000
Performance Shares [Member] | Neat PHA Revenue Metric [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting description			30% of the shares are subject to a total PHA revenue metric based on 2024 financial results. 50% of these shares vest if total PHA revenue is $151 million, 100% vest if total PHA revenue is $189 million or higher, with prorated vesting between $151 million and $189 million.
Performance Shares [Member] | Neat PHA Revenue Metric [Member] | Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			$ 189,000
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)			189,000
Performance Shares [Member] | Neat PHA Revenue Metric [Member] | Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			151,000
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)			$ 151,000
Stock Option
Stock-Based Compensation (Details) [Line Items]
Share-based compensation, Issued shares		0
Stock options			972,222
Long term liability		$ 400				400
Stock Option | Selling, general and administrative [Member]
Stock-Based Compensation (Details) [Line Items]
Stock-based compensation expense		$ 200				300
Market Based Restricted Shares [Member]
Stock-Based Compensation (Details) [Line Items]
Number of restricted shares issued		0		0
Stock-based compensation expense		$ 4,600		$ 4,800		$ 9,200	$ 6,000
Cash Settled Options [Member]
Stock-Based Compensation (Details) [Line Items]
Performance stock and performance stock units						535,641
Cash Settled Options [Member] | Third anniversary [Member]
Stock-Based Compensation (Details) [Line Items]
Number of Shares, Granted							1,710,947
2020 ESPP [Member]
Stock-Based Compensation (Details) [Line Items]
ESPP plan, percentage of stock discount						15%
Share-based compensation, authorized shares		2,571,737				2,571,737
Share-based compensation, Issued shares						83,180
2020 Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Shares Outstanding						1,153,642
Share-based compensation, remained authorized for Issuance		1,736,571				1,736,571			213,997
Number of restricted shares issued		0		0
Stock-based compensation expense		$ 4,800		$ 5,000		$ 9,500	$ 6,200
Legacy Stock Plans [Member]
Stock-Based Compensation (Details) [Line Items]
Share-based compensation, authorized shares								2,895,411

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of stock based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expensed and Capitalized, Amount	$ 14,547	$ 14,031	$ 28,245	$ 20,696
Cost of revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expensed and Capitalized, Amount	10	28	39	53
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expensed and Capitalized, Amount	12,707	12,245	24,572	18,026
Research and Development ]Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expensed and Capitalized, Amount	$ 1,830	$ 1,758	$ 3,634	$ 2,617

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of stock option activity under our equity plans - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended	12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2022	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Number of Shares, Beginning	11,227,250	10,589,010		10,589,010
Number of Shares, Granted	221,892	688,240
Number of shares, exercised	(10,000)	(50,000)
Number of Shares, Exercisable	4,473,003			4,473,003
Number of Shares, Ending	11,439,142	11,227,250		11,439,142	10,589,010
Number of Shares, Vested and expected to vest	11,439,142			11,439,142
Weighted Average Exercise Price, Beginning (in Dollars per share)	$ 14.24	$ 14.85		$ 14.85
Weighted Average Exercise Price, Granted (in Dollars per share)	4.07	3.96
Weighted Average Exercise Price, Exercised (in Dollars per share)	3.28	3.28
Weighted Average Exercise Price, Ending (in Dollars per share)	14.05	$ 14.24		14.05	$ 14.85
Weighted Average Exercise Price, Exercisable (in Dollars per share)	4.84			4.84
Weighted Average Exercise Price, Vested and expected to vest (in Dollars per share)	$ 14.05			$ 14.05
Weighted Average Remaining Contractual Term (Years)	7 years 1 month 17 days		7 years 3 months 25 days		7 years 4 months 20 days
Weighted Average Remaining Contractual Term (Years), Exercisable				4 years 9 months 7 days
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest				7 years 1 month 17 days
Aggregate Intrinsic Value, Beginning (in Dollars)	$ 11,642,645	$ 22,473,835		$ 22,473,835
Aggregate Intrinsic Value, Exercised (in Dollars)	18,300	81,300
Aggregate Intrinsic Value, Ending (in Dollars)	5,637,529	$ 11,642,645		5,637,529	$ 22,473,835
Aggregate Intrinsic Value, Exercisable (in Dollars)	5,114,474			5,114,474
Aggregate Intrinsic Value, Vested and expected to vest (in Dollars)	$ 5,637,529			$ 5,637,529

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of share based compensation activity (Details) - $ / shares	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	11,227,250		11,439,142	10,589,010
September 30, 2021 fair value	$ 1.77	$ 18.52	$ 1.84

Commitments and Contingencies A

Commitments and Contingencies Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Royalty per share (in Pounds per share)	$ 0.05
Weight of PHA Sold (in Pounds)	$ 500,000
Decrease royalty per share (in Pounds per share)	$ 0.025
Royalties amount	$ 200	$ 200
Date of dismissal	Jul. 21, 2022
Loss Contingency, Actions Taken by Plaintiff	Plaintiffs have now confirmed that, based on Defendants’ arguments in the motion to dismiss, Plaintiffs have dropped seven of the nine counts, eliminating all of the Securities Act counts specifically relating to the proxy solicitation, registration statements and related control person claims, and all that now remains are the first two counts under Rules 10(b)-5(a)-(c) of the Exchange Act and control person liability. Additionally, all of the Defendants other than Danimer and three of its current or former officers or directors have been dismissed from the case.
Anticipated construction	$ 90,600
Accrued expenses	$ 600		$ 1,250

Subsequent Events (Additional I

Subsequent Events (Additional Information) (Details) $ in Millions	3 Months Ended
	Sep. 30, 2022 USD ($)
Subsequent Event [Member]
Subsequent Event [Line Items]
Amortization of Debt Issuance Costs	$ 1.4